AU Patent

AU2024204906A1 — Acalabrutinib maleate dosage forms

Assigned to Acerta Pharma BV · Expires 2024-08-01 · 2y expired

What this patent protects

OF THE DISCLOSURE The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharma…

USPTO Abstract

OF THE DISCLOSURE The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024204906A1
Jurisdiction
AU
Classification
—
Expires
2024-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Acerta Pharma BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.